BAD
BAD (Bcl2-associated agonist of cell death, also known as BCL2L8 and BBC2) is a BH3-only member of the Bcl-2 family that promotes cell death. It binds anti-apoptotic Bcl-2 family proteins and links growth factor receptor signalling to the apoptotic machinery. Browse Assay Genie's current range of BAD research reagents below, or read on for the biology behind the target.
BAD is a pro-apoptotic regulator of programmed cell death. It competes for binding to Bcl-X(L), Bcl-2 and Bcl-W, and in doing so alters the level of heterodimerisation of these proteins with BAX. Through heterodimers with BCL-xL and BCL-2, BAD reverses their death repressor activity. The effect is not equal across partners: BAD can reverse the death repressor activity of Bcl-X(L), but not that of Bcl-2. UniProt describes it as appearing to act as a link between growth factor receptor signalling and the apoptotic pathways.
The BAD gene encodes a member of the Bcl-2 family and belongs to the HGUC gene group of BCL2 homology region 3 (BH3) only proteins. The protein is found at the outer mitochondrial membrane and in the cytoplasm. Alternative splicing of the gene produces two transcript variants that encode the same isoform, so researchers studying the BAD protein are working with a single polypeptide sequence.
The proapoptotic activity of BAD is regulated through phosphorylation. The protein kinases AKT and MAP kinase, together with the protein phosphatase calcineurin, have been implicated in controlling this regulation. This places BAD at the point where survival signalling and cell death pathways meet, which is why it is widely examined in studies of apoptosis, growth factor signalling and the Bcl-2 family. Orthologues of the gene are present in mouse and rat (both named Bad), allowing comparative work in rodent models.
BAD promotes cell death by competing for binding to Bcl-X(L), Bcl-2 and Bcl-W, making it a core component of Bcl-2 family studies.
BAD appears to link growth factor receptor signalling with apoptotic pathways, so it is used to study how survival cues influence cell fate.
The proapoptotic activity of BAD is regulated by phosphorylation, with AKT, MAP kinase and calcineurin involved in its regulation.
BAD alters heterodimerisation of Bcl-X(L), Bcl-2 and Bcl-W with BAX, offering a model for examining BH3-only protein selectivity.
BAD positively regulates apoptosis. It binds Bcl-X(L), Bcl-2 and Bcl-W, affecting how these proteins heterodimerise with BAX, and can reverse the death repressor activity of Bcl-X(L) but not Bcl-2. It also appears to connect growth factor receptor signalling with apoptotic pathways.
BAD stands for BCL2 associated agonist of cell death, and is also known as BCL2L8 and BBC2. Alternative splicing of the gene gives two transcript variants, but both encode the same isoform, so only one protein form is produced.
The gene has orthologues named Bad in mouse and rat. In terms of regulation, its proapoptotic activity is controlled by phosphorylation, involving the kinases AKT and MAP kinase and the phosphatase calcineurin. Check the datasheet of any product for its validated reactivity.
Other Bcl-2 family members, regulatory kinases and phosphatases, and apoptosis pathway markers.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q92934; product specifications from Assay Genie datasheets.